Myotonic Dystrophy Drug Market 2022 Growth, COVID Impact, Trends Analysis Report 2028
The global myotonic dystrophy drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Myotonic dystrophy is a muscular dystrophy caused by a long-term genetic mutation. It is the most common type of muscular dystrophy in adulthood, affecting roughly one out of every 8,000 people. Muscle atrophy and weakness worsen over time as a symptom. Muscles contract frequently and take a long time to relax. Some people have a relatively mild type, while others have a severe one that affects them from birth. This is owing to the condition's molecular foundation, which is caused by a dynamic mutation called a triplet repeat expansion, which occurs when three base pairs of DNA are present in varied copies numbers.
To Request a Sample of our Report on Myotonic Dystrophy
Drug Market: https://www.omrglobal.com/request-sample/myotonic-dystrophy-drug-market
The primary factor propelling the growth of global
myotonic dystrophy market is the introduction of novel disease therapeutics and
increased R&D activities. For instance, in November 2021, Locanabio, Inc.,
a genetic pharmaceuticals business focused on developing therapies for patients
with severe neuromuscular, neurodegenerative, and retinal illnesses, announced
new preclinical data from its myotonic dystrophy type 1 (DM1) program.
Locanabio scientists used their CORRECTx platform to show a dose-dependent
reduction in toxic CUG foci in both DM1 patient muscle cells and a preclinical
mouse model of DM1, which resulted in an alternative RNA splicing correction
and a statistically significant reduction in myotonia, or muscle weakness.
Further, in April 2020, Scientists from the University's Schools of Life
Sciences and Chemistry have discovered that inhibiting a molecule in patients'
cells called CDK12 can potentially develop a therapy to alleviate some of the
symptoms and support treat this incurable condition.
Some major key players in the market include Isis
Pharmaceuticals, Inc., and Lupin Ltd., among others. The market players are
contributing significantly to the growth of the market by the adoption of
various strategies including mergers & acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, in October 2021, AOC 1001 has been
granted Fast Track designation by the Food and Drug Administration (FDA) for
the treatment of myotonic dystrophy type 1 (DM1). AOC 1001 is a monoclonal
antibody that binds to transferrin receptor 1 and is coupled to a short
interfering RNA that targets DMPK mRNA. AOC 1001 is expected to address the
fundamental cause of DM1 by lowering DMPK mRNA levels in skeletal, cardiac, and
smooth muscle. Data from preclinical tests back up the designation,
showing that AOC 1001 successfully transported the small interfering RNA to
muscle cells, resulting in dose-dependent decreases in DMPK mRNA.
Market Coverage
·
The market number available for – 2021-2028
·
Base year- 2021
·
Forecast period- 2022-2028
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Isis Pharmaceuticals, Inc., and Lupin Ltd., among
others.
(Get 15% Discount on Buying this Report)
A
full Report of Myotonic Dystrophy Drug Market
is Available @ https://www.omrglobal.com/industry-reports/myotonic-dystrophy-drug-market
Global Myotonic Dystrophy Drug Market Report by Segment
By Type
·
Myotonic Dystrophy Type 1 (DM1)
·
Myotonic Dystrophy Type 2 (DM2)
By Application
·
Hospital
·
Clinic
·
Others
Global Myotonic Dystrophy Drug Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no:
+91 7803040404
Comments
Post a Comment